199 related articles for article (PubMed ID: 11160773)
21. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
Bright JM; Dowers K; Powers BE
Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
[TBL] [Abstract][Full Text] [Related]
22. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
23. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Ito T; Koide T; Maruyama I
Thromb Haemost; 2013 Jan; 109(1):102-11. PubMed ID: 23179055
[TBL] [Abstract][Full Text] [Related]
24. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
[TBL] [Abstract][Full Text] [Related]
25. [The anti-platelet aggregation drugs: new approaches based on snake venom polypeptides].
Marrakchi N; Guermazi S; El Ayeb M
Arch Inst Pasteur Tunis; 1997; 74(1-2):9-15. PubMed ID: 15945171
[No Abstract] [Full Text] [Related]
26. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Mousa SA
Curr Pharm Des; 2003; 9(28):2317-22. PubMed ID: 14529393
[TBL] [Abstract][Full Text] [Related]
27. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
28. 8th Seah Cheng Siang Memorial Lecture: new antithrombotic agents.
Verstraete M
Ann Acad Med Singap; 1999 May; 28(3):347-62. PubMed ID: 10575518
[TBL] [Abstract][Full Text] [Related]
29. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
30. The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
Gurbel PA; Tantry US
J Interv Cardiol; 2008 Dec; 21 Suppl 1():S10-7. PubMed ID: 19090932
[TBL] [Abstract][Full Text] [Related]
31. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
Siller-Matula J; Schrör K; Wojta J; Huber K
Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
[TBL] [Abstract][Full Text] [Related]
32. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
[TBL] [Abstract][Full Text] [Related]
33. The hookworm platelet inhibitor: functional blockade of integrins GPIIb/IIIa (alphaIIbbeta3) and GPIa/IIa (alpha2beta1) inhibits platelet aggregation and adhesion in vitro.
Chadderdon RC; Cappello M
J Infect Dis; 1999 May; 179(5):1235-41. PubMed ID: 10191228
[TBL] [Abstract][Full Text] [Related]
34. [Antiplatelet therapy].
Ikeda Y
Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1802-11. PubMed ID: 10581767
[No Abstract] [Full Text] [Related]
35. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.
Mazur P; Frołow M; Niżankowski R; Sadowski J; Undas A
Platelets; 2013; 24(2):151-5. PubMed ID: 22497730
[TBL] [Abstract][Full Text] [Related]
36. Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study.
De Luca G; Secco GG; Iorio S; Verdoia M; Bellomo G; Marino P
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):756-9. PubMed ID: 23135381
[TBL] [Abstract][Full Text] [Related]
37. [Pharmazie in unserer Zeit 4/2009].
Alban S; Dingermann T
Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
[No Abstract] [Full Text] [Related]
38. Platelet ADP receptor antagonists: ticlopidine and clopidogrel.
Jacobson AK
Best Pract Res Clin Haematol; 2004 Mar; 17(1):55-64. PubMed ID: 15171957
[TBL] [Abstract][Full Text] [Related]
39. Positional importance of Pro53 adjacent to the Arg49-Gly50-Asp51 sequence of rhodostomin in binding to integrin alphaIIbbeta3.
Chang CP; Chang JC; Chang HH; Tsai WJ; Lo SJ
Biochem J; 2001 Jul; 357(Pt 1):57-64. PubMed ID: 11415436
[TBL] [Abstract][Full Text] [Related]
40. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.
Comerota AJ
Atheroscler Suppl; 2005 Dec; 6(4):13-9. PubMed ID: 16275168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
